| Attribute |
Value |
| 52 Week Change |
0.15999997 |
| Address1 |
2 Holzman Street |
| Address2 |
Science Park PO Box 4081 |
| All Time High |
17.95 |
| All Time Low |
3.02 |
| Ask |
9.97 |
| Ask Size |
2 |
| Average Analyst Rating |
1.0 - Strong Buy |
| Average Daily Volume10 Day |
80,630 |
| Average Daily Volume3 Month |
121,192 |
| Average Volume |
121,192 |
| Average Volume10Days |
80,630 |
| Beta |
0.132 |
| Bid |
5.62 |
| Bid Size |
2 |
| Book Value |
4.657 |
| City |
Rehovot |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
Israel |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
7.7657 |
| Current Ratio |
4.06 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
7.91 |
| Day Low |
7.7657 |
| Debt To Equity |
4.378 |
| Display Name |
Kamada |
| Dividend Date |
1,789,603,200 |
| Dividend Rate |
0.17 |
| Dividend Yield |
2.17 |
| Earnings Call Timestamp End |
1,786,537,800 |
| Earnings Call Timestamp Start |
1,786,537,800 |
| Earnings Growth |
0.231 |
| Earnings Quarterly Growth |
0.256 |
| Earnings Timestamp |
1,786,537,800 |
| Earnings Timestamp End |
1,794,227,400 |
| Earnings Timestamp Start |
1,794,227,400 |
| Ebitda |
41,494,000 |
| Ebitda Margins |
0.21628 |
| Enterprise To Ebitda |
9.518 |
| Enterprise To Revenue |
2.059 |
| Enterprise Value |
394,927,136 |
| Eps Current Year |
0.4775 |
| Eps Forward |
0.57667 |
| Eps Trailing Twelve Months |
0.38 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,787,788,800 |
| Exchange |
NMS |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fax |
972 8 940 6473 |
| Fifty Day Average |
8.1106 |
| Fifty Day Average Change |
-0.3449006 |
| Fifty Day Average Change Percent |
-0.04252467 |
| Fifty Two Week Change Percent |
15.999996 |
| Fifty Two Week High |
9.35 |
| Fifty Two Week High Change |
-1.5843005 |
| Fifty Two Week High Change Percent |
-0.1694439 |
| Fifty Two Week Low |
6.55 |
| Fifty Two Week Low Change |
1.2156997 |
| Fifty Two Week Low Change Percent |
0.185603 |
| Fifty Two Week Range |
6.55 - 9.35 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,370,007,000,000 |
| Float Shares |
33,184,009 |
| Forward Eps |
0.57667 |
| Forward P E |
13.466454 |
| Free Cashflow |
15,506,375 |
| Full Exchange Name |
NasdaqGS |
| Full Time Employees |
462 |
| Fullday Change |
-0.06430006 |
| Fullday Change Percent |
-0.82120126 |
| Fullday Price |
7.7657 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.4082 |
| Gross Profits |
78,312,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.06992 |
| Held Percent Institutions |
0.49221 |
| Implied Shares Outstanding |
57,710,305 |
| Industry |
Drug Manufacturers - Specialty & Generic |
| Industry Disp |
Drug Manufacturers - Specialty & Generic |
| Industry Key |
drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Dividend Date |
1,787,788,800 |
| Last Dividend Value |
0.17 |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. |
| Long Name |
Kamada Ltd. |
| Market |
us_market |
| Market Cap |
448,160,896 |
| Market State |
REGULAR |
| Max Age |
86,400 |
| Message Board Id |
finmb_9002466 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
22,252,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
510,725,909 |
| Number Of Analyst Opinions |
4 |
| Open |
7.83 |
| Operating Cashflow |
35,759,000 |
| Operating Margins |
0.17316 |
| Payout Ratio |
0.65790004 |
| Peg Ratio |
0.57 |
| Phone |
972 8 940 6472 |
| Previous Close |
7.83 |
| Price Eps Current Year |
16.263247 |
| Price Hint |
2 |
| Price To Book |
1.6675327 |
| Price To Sales Trailing12 Months |
2.3360085 |
| Profit Margins |
0.11599 |
| Quick Ratio |
2.293 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.0 |
| Region |
US |
| Regular Market Change |
-0.06430006 |
| Regular Market Change Percent |
-0.82120126 |
| Regular Market Day High |
7.91 |
| Regular Market Day Low |
7.7657 |
| Regular Market Day Range |
7.7657 - 7.91 |
| Regular Market Open |
7.83 |
| Regular Market Previous Close |
7.83 |
| Regular Market Price |
7.7657 |
| Regular Market Time |
1,792,169,096 |
| Regular Market Volume |
17,575 |
| Return On Assets |
0.0463 |
| Return On Equity |
0.08405 |
| Revenue Growth |
0.227 |
| Revenue Per Share |
3.284 |
| Sand P52 Week Change |
0.16207206 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
57,710,305 |
| Shares Percent Shares Out |
0.0036000002 |
| Shares Short |
209,476 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
156,782 |
| Short Name |
Kamada Ltd. |
| Short Percent Of Float |
0.0067000003 |
| Short Ratio |
1.46 |
| Source Interval |
15 |
| Symbol |
KMDA |
| Target High Price |
15.0 |
| Target Low Price |
11.0 |
| Target Mean Price |
13.5 |
| Target Median Price |
14.0 |
| Total Cash |
70,133,000 |
| Total Cash Per Share |
1.212 |
| Total Debt |
11,801,000 |
| Total Revenue |
191,848,992 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.25 |
| Trailing Annual Dividend Yield |
0.03192848 |
| Trailing Eps |
0.38 |
| Trailing P E |
20.436052 |
| Trailing Peg Ratio |
0.6613 |
| Triggerable |
1 |
| Two Hundred Day Average |
8.0097 |
| Two Hundred Day Average Change |
-0.24399996 |
| Two Hundred Day Average Change Percent |
-0.030463059 |
| Type Disp |
Equity |
| Volume |
17,575 |
| Website |
https://www.kamada.com |
| Zip |
7,670,402 |